NHAS
KZR

Novo Holdings A/S’s Kezar Life Sciences KZR Stock Holding History

Novo Holdings A/S’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-46,560
Closed -$1.46M – 42
2023
Q1 		$1.46M Sell
46,560
-70,940
-60% -$4.1M 0.1% 46
2022
Q4 		$8.27M Buy
117,500
+57,662
+96% +$4.28M 0.52% 38
2022
Q3 		$5.15M Buy
+59,838
New +$5.81M 0.25% 45

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Novo Holdings A/S's KZR Position: Q2 2023 in Review

Novo Holdings A/S sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 46,560 shares — an estimated $1.46M sold.

Novo Holdings A/S first reported a position in KZR in Q3 2022 and held it in 3 quarters. The position peaked at $8.27M in Q4 2022. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Novo Holdings A/S reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Novo Holdings A/S sold 46,560 Kezar Life Sciences shares in Q2 2023, an estimated $1.46M.
  • Novo Holdings A/S first reported a position in Kezar Life Sciences in Q3 2022 and held it in 3 quarters.
  • Novo Holdings A/S's Kezar Life Sciences position peaked at $8.27M in Q4 2022.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Novo Holdings A/S's 13F filing for Q2 2023, filed 14 Aug 2023.